Top

Published in:

Open Access 01-11-2018 | Breast

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients

Authors: Bas H. M. van der Velden, Elizabeth J. Sutton, Luca A. Carbonaro, Ruud M. Pijnappel, Elizabeth A. Morris, Kenneth G. A. Gilhuijs

Published in: European Radiology | Issue 11/2018

Abstract

Objectives

To assess whether contralateral parenchymal enhancement reproduces as an independent biomarker for patient survival in an independent patient cohort from a different cancer institution.

Methods

This is a HIPAA-compliant IRB approved retrospective study. Patients with ER-positive/HER2-negative operable invasive ductal carcinoma and preoperative dynamic contrast-enhanced MRI were consecutively included between 2005 and 2009. The parenchyma of the breast contralateral to known cancer was segmented automatically on MRI and contralateral parenchymal enhancement (CPE) was calculated. CPE was split into tertiles and tested for association with invasive disease-free survival (IDFS) and overall survival (OS). Propensity score analysis with inverse probability weighting (IPW) was used to adjust CPE for patient and tumour characteristics as well as systemic therapy.

Results

Three hundred and two patients were included. The median age at diagnosis was 48 years (interquartile range, 42-57). Median follow-up was 88 months (interquartile range, 76-102); 15/302 (5%) patients died and 37/302 (13%) had a recurrence or died. In context of multivariable analysis, IPW-adjusted CPE was associated with IDFS [hazard ratio (HR) = 0.27, 95% confidence interval (CI) = 0.05-0.68, p = 0.004] and OS (HR = 0.22, 95% CI = 0.00-0.83, p = 0.032).

Conclusions

Contralateral parenchymal enhancement on pre-treatment dynamic contrast-enhanced MRI as an independent biomarker of survival in patients with ER-positive/HER2-negative breast cancer has been upheld in this study. These findings are a promising next step towards a practical and inexpensive test for risk stratification of ER-positive/HER2-negative breast cancer.

Key points

• High parenchymal-enhancement in the disease-free contralateral breast reproduces as biomarker for survival.

• This is in patients with ER-positive/HER2-negative breast cancer from an independent cancer centre.

• This is independent of patient and pathology parameters and systemic therapy.

De Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119–126CrossRef

Galea MH, Blamey RW, Ellis IO, Elston CE (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207–219CrossRef

Wishart GC, Azzato EM, Greenberg DC et al (2010) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12:R1CrossRef

Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991CrossRef

van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef

Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826CrossRef

Cardoso F, van’t Veer LJ, Bogaerts J et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729CrossRef

Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014CrossRef

Kurose K, Gilley K, Matsumoto S et al (2002) Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32:355–357CrossRef

10.

Boyd NF, Martin LJ, Bronskill M et al (2010) Breast tissue composition and susceptibility to breast cancer. JNCI J Natl Cancer Inst 102:1224–1237CrossRef

11.

King V, Brooks JD, Bernstein JL et al (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260:50–60CrossRef

12.

Hattangadi J, Park C, Rembert J et al (2008) Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. AJR Am J Roentgenol 190:1630–1636CrossRef

13.

Jones EF, Sinha SP, Newitt DC et al (2013) MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One 8:e61969CrossRef

14.

Telegrafo M, Rella L, Stabile Ianora AA et al (2016) Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancer. Magn Reson Imaging 34:173–176CrossRef

15.

Preibsch H, Wanner L, Bahrs SD et al (2016) Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol 26:1590–1596CrossRef

16.

Chen JH, Yu HJ, Hsu C et al (2015) Background parenchymal enhancement of the contralateral normal breast: association with tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Transl Oncol 8:204–209CrossRef

17.

Choi JS, Ko ES, Ko EY et al (2016) Background parenchymal enhancement on preoperative magnetic resonance imaging: association with recurrence-free survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) 95:e3000CrossRef

18.

van der Velden BHM, Dmitriev I, Loo CE et al (2015) Association between parenchymal enhancement of the contralateral breast in dynamic contrast-enhanced MR imaging and outcome of patients with unilateral invasive breast cancer. Radiology 276:675–685CrossRef

19.

van der Velden BHM, Elias SG, Bismeijer T et al (2017) Complementary value of contralateral parenchymal enhancement on DCE-MRI to prognostic models and molecular assays in high-risk ER⁺/HER2^- breast cancer. Clin Cancer Res 23:6505–6515CrossRef

20.

McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184CrossRef

21.

Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. https://doi.org/10.1200/JCO.2009.25.6529 CrossRefPubMedPubMedCentral

22.

Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377CrossRef

23.

Tustison NJ, Avants BB, Cook PA et al (2010) N4ITK: Improved N3 bias correction. IEEE Trans Med Imaging 29:1310–1320CrossRef

24.

Gilhuijs KGA, Deurloo EE, Muller SH et al (2002) Breast MR imaging in women at increased lifetime risk of breast cancer: clinical system for computerized assessment of breast lesions—initial results. Radiology 225:907–916CrossRef

25.

Klifa C, Carballido-Gamio J, Wilmes L et al (2004) Quantification of breast tissue index from MR data using fuzzy clustering. Conf Proc IEEE Eng Med Biol Soc 3:1667–1670PubMed

26.

Dmitriev ID, Loo CE, Vogel WV et al (2013) Fully automated deformable registration of breast DCE-MRI and PET/CT. Phys Med Biol 58:1221–1133CrossRef

27.

Gribbestad IS, Nilsen G, Fjøsne HE et al (1994) Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J Magn Reson Imaging 4:477–480CrossRef

28.

Hudis CA, Barlow WE, Costantino JP et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132CrossRef

29.

Curtis LH, Hammill BG, Eisenstein EL et al (2007) Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 45:S103–S107CrossRef

30.

van Buuren S, Groothuis-Oudshoorn K (2011) Mice: multivariate imputation by chained equations in R. J Stat Softw 45:1–67CrossRef

31.

Simpson ER (2003) Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86:225–230CrossRef

32.

Jordan VC (1993) Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507–517CrossRef

33.

Rooney MS, Shukla SA, Wu CJ et al (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48–61CrossRef

34.

Morris EA (2007) Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 45:863–880CrossRef

35.

Dontchos BN, Rahbar H, Partridge SC et al (2015) Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology 276:371–380CrossRef

36.

Hylton NM (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24:3293–3298CrossRef

37.

Wu J, Li B, Sun X et al (2017) Heterogeneous enhancement patterns of tumor-adjacent parenchyma at mr imaging are associated with dysregulated signaling pathways and poor survival in breast cancer. Radiology 285:401–413CrossRef

38.

Chan HM, van der Velden BHM, Loo CE, Gilhuijs KGA (2017) Eigentumors for prediction of treatment failure in patients with early-stage breast cancer using dynamic contrast-enhanced MRI: a feasibility study. Phys Med Biol 62:6467–6485CrossRef

Title: Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients
Authors: Bas H. M. van der Velden
Elizabeth J. Sutton
Luca A. Carbonaro
Ruud M. Pijnappel
Elizabeth A. Morris
Kenneth G. A. Gilhuijs
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 11/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-018-5470-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients

Abstract

Objectives

Methods

Results

Conclusions

Key points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key points

Please log in to get access to this content

Other articles of this Issue 11/2018

Quantitative MR spectroscopy reveals metabolic changes in the dorsolateral prefrontal cortex of patients with temporal lobe epilepsy

The 3D reconstructions of female pelvic autonomic nerves and their related organs based on MRI: a first step towards neuronavigation during nerve-sparing radical hysterectomy

LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results

Coronary artery calcium assessed with calibrated mass scoring in asymptomatic individuals: results from the Copenhagen General Population Study

Correction to: Applicability and accuracy of pretest probability calculations implemented in the NICE clinical guideline for decision making about imaging in patients with chest pain of recent onset

Fast 3-T MR-guided transrectal prostate biopsy using an in-room tablet device for needle guide alignment: a feasibility study